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ABSTRACT 
Recessive dystrophic epidermolysis bullosa (RDEB) is a rare monogenic blistering disorder 
caused by lack of functional type VII collagen, leading to skin fragility and subsequent trauma-
induced separation of the epidermis from the underlying dermis. 46% of RDEB patients harbor 
at least one premature termination codon (PTC) mutation in COL7A1 and previous studies have 
shown that aminoglycosides are able to overcome RDEB PTC mutations by inducing “read-
through” and incorporation of an amino acid at the PTC site. However, aminoglycoside toxicity 
will likely prevent widespread clinical application. Here the FDA-approved drug amlexanox was 
tested for its ability to read-through PTC mutations in RDEB patient derived cells. Eight of 12 
different PTC alleles responded to treatment and produced full length protein, in some cases over 
50% relative to normal controls. Read-through type VII collagen was readily detectable in cell 
culture media and also localized to the dermal-epidermal junction in organotypic skin culture. 
Amlexanox increased COL7A1 transcript and the phosphorylation of UPF-1, an RNA helicase 
associated with nonsense mediated mRNA decay (NMD), suggesting that amlexanox inhibits 
NMD in RDEB patient cells that read-through. This pre-clinical study demonstrates the potential 
of re-purposing amlexanox for treatment of RDEB patients harboring PTC mutation in COL7A1.  
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INTRODUCTION 
Epidermolysis bullosa (EB) is a group of  inherited blistering diseases caused by mutations in 
genes encoding proteins critical for skin integrity (Fine et al., 2014). Dystrophic EB is caused by 
mutations in COL7A1 leading to defective type VII collagen, a protein that localizes to the 
basement membrane zone (BMZ) and provides adhesion of the epidermis to the dermis through 
interaction with collagen IV, laminin 332, and collagen I (Brittingham et al., 2006; Chen et al., 
1999; Villone et al., 2008). Both keratinocytes and fibroblasts synthesize and secrete type VII 
collagen which, after cleavage of the non-collagenous carboxy-terminal NC2 domain, assembles 
in antiparallel tail-to-tail dimers which subsequently aggregate to form anchoring fibrils 
(Bruckner-Tuderman et al., 1995; Chung and Uitto, 2010). The proper assembly of anchoring 
fibrils is required for stable attachment between the epidermis and dermis and inability to form 
anchoring fibrils due to genetic mutation in COL7A1 results in skin fragility, trauma-induced 
blistering followed by chronic wounds with poor healing and excessive scarring. The recessive 
form of dystrophic EB (recessive dystrophic EB, RDEB; OMIM #226600) is often a devastating 
disorder, leading to extensive skin blistering, nail dystrophy, alopecia, and mitten deformities of 
the hands and feet. Extracutaneous involvement of esophageal and other mucosal epithelium 
further complicates this disease (Fine et al., 2014; Fine and Mellerio, 2009) and RDEB patients 
suffer from excessive fibrosis at the sites of tissue damage associated with development of 
aggressive and frequently fatal squamous cell carcinomas (Fine et al., 2009; Mittapalli et al., 
2016; Ng et al., 2012).  A correlation exists between the amount of type VII collagen present at 
the BMZ and the severity of the disease (McGrath et al., 1993). Premature termination codon 
mutations (PTCs) in COL7A1 are reported in about 46% of RDEB patients (van den Akker et al., 
2011; Wertheim-Tysarowska et al., 2012), and those individuals harboring two PTC mutations 
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(around 10% of cases reported) express very low amounts, if any, of truncated type VII collagen 
and have the most severe subtype of the disease - RDEB-severe generalized (Fine et al., 2014). 
Significant progress toward development of therapeutic approaches for RDEB has been made in 
recent years (Uitto et al., 2016). Treatment strategies that have shown promising pre-clinical data 
include bone marrow stem cell transplantation (Liao et al., 2015; Tamai et al., 2011; Tolar et al., 
2009), viral delivery of COL7A1 to correct expression ex-vivo (Chen et al., 2002; Jackow et al., 
2016; Siprashvili et al., 2010), and protein therapy (Woodley et al., 2013). However, those 
approaches that have translated into the clinic are not without complications - in some cases they 
result in significant mortality (Wagner et al., 2010) or involve long and expensive procedures 
dependent on specialized equipment and infrastructure (Siprashvili et al., 2016). More recently, 
RNA editing approaches have shown preclinical promise (Bremer et al., 2016; Goto et al., 2006; 
Titeux et al., 2010; Turczynski et al., 2016), and gene correction by read-through of PTC 
mutations has been demonstrated in vitro (Cogan et al., 2014). In the latter study, read-through of 
COL7A1 PTC mutations by aminoglycosides demonstrated efficient expression of full length 
type VII collagen protein in patient cells with homozygous PTC mutations. However, systemic 
long term administration of aminoglycosides, such as gentamicin, can be associated with 
toxicity, mainly ototoxity and kidney failure (Tokgoz et al., 2010; Walker and Shah, 1987), 
which will ultimately slow down translation of this drug into clinical practice.  
In this study, read-through efficacy of amlexanox, an FDA approved drug previously reported to 
induce read-through in human cells (Gonzalez-Hilarion et al., 2012), was evaluated in RDEB 
patient cells in vitro. Amlexanox was initially approved for the treatment of mouth ulcers and is 
currently in Phase II clinical trials for diabetes mellitus type II (www.clinicaltrials.gov). Here 
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pre-clinical evidence is presented supporting amelxanox for treatment of RDEB patients 
harboring PTC mutation in COL7A1. 
 
RESULTS 
Amlexanox induces full length type VII collagen synthesis in RDEB fibroblasts and 
keratinocytes with COL7A1 PTC mutation 
Previous reports have shown that amlexanox is well tolerated by cultured cells, showing little 
toxicity up to 125 µM concentrations (Gonzalez-Hilarion et al., 2012). In agreement with these 
previous studies, incubation of skin fibroblasts and keratinocytes with amlexanox showed little 
toxicity up to 250 µM, although growth was retarded over 48 hours at higher concentrations 
(Figure S1 and data not shown). Next, RDEB patient cells harboring homozygous COL7A1 PTC 
mutation (p.Q251X) were incubated with a range of amlexanox concentrations, and 250 µM was 
identified as the concentration inducing greatest level of full length type VII collagen expression 
after 48 hours (Figure S2). This dose was used for all subsequent experiments. Amlexanox and 
gentamicin were then assessed for read-through in cells derived from 14 RDEB patients 
harboring 12 different PTC mutations. After 48 hours of treatment with amlexanox, increased 
full length type VII collagen (290 kDa) was observed by Western blot analysis of total cell 
lysates from RDEB keratinocytes and fibroblasts isolated from eight RDEB patients. In total, 
four out of 12 PTC mutations did not show evidence of read-through (Table 1) either with 
amlexanox or with gentamicin. In those samples with homozygous PTC mutations that 
responded to treatment, a higher efficacy of read-through with amlexanox, compared to 
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gentamicin was observed (Figure 1). In cells with compound heterozygous PTC/missense 
mutations (p.G2073D/p.R578X) a clear increase in type VII collagen in total cell lysate was not 
apparent due to the large amount of intracellular protein as result of the presence of the missense 
mutation (Figure 2a). Overall, read-through induced either by amlexanox or by gentamicin was 
only observed in those patient cells which expressed detectable levels of full length type VII 
collagen, albeit at considerably lower levels and presumably as a result of endogenous read-
through (Figure 1).  
Read-through type VII collagen is stable in cell culture media and localizes to the dermal-
epidermal junction in organotypic culture 
To evaluate whether read-through type VII collagen protein is functional, Western blotting of 
proteins isolated from cell culture media was performed and fibrinogen based organotypic skin 
equivalent cultures using either RDEB or normal cells were prepared. Substitution of a 
pathogenic missense mutation in place of a PTC could affect proper assembly and post-
translational modification of type VII collagen. Collagen triple helix formation is necessary to 
protect type VII collagen monomers from proteolytic degradation after secretion (Christiano et 
al., 1996) and mutations in the non-collagenous domains can affect protein-protein binding at the 
BMZ (Brittingham et al., 2006). Western blotting of proteins collected from p.G2073D/p.R578X 
and p.R2610X/p.R2610X keratinocyte culture media after treatment with amlexanox and 
gentamicin showed increased levels of full length type VII collagen (Figure 2b), demonstrating 
stability of read-through protein. 
To assess correct dermal-epidermal junction (DEJ) deposition of read-through type VII collagen, 
organotypic cultures were prepared and treated with amlexanox for 2 weeks. Read-through type 
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VII collagen at the DEJ was then evaluated by immunofluorescence using a type VII collagen 
specific antibody raised against the N-terminal, non-collagenous domain. Notable increase in 
type VII collagen at the DEJ in the RDEB p.Q251X/p.Q251X culture was apparent after two 
weeks of treatment (Figure 2c). An increase in type VII collagen synthesis in RDEB 
p.R578X/p.Q906X organotypic culture was also observed (Figure S3), however, a significant 
amount of intracellular type VII collagen was also detected making it difficult to identify a 
difference at the DEJ. The RDEB culture prepared with G2073D/R578X cells did not show a 
clear difference in type VII collagen synthesis between treated and non-treated control, which is 
likely due to the high levels of intracellular protein previously detected by Western blotting 
(Figure 2a) making it difficult to distinguish an increase at the DEJ (Figure S3). 
Amlexanox increases COL7A1 transcript levels and phosphorylation of the RNA helicase 
UPF1  
Amlexanox has previously been shown to inhibit nonsense mediated mRNA decay (NMD) in 
cell based reporter assays (Gonzalez-Hilarion et al., 2012). To investigate whether amlexanox 
increases COL7A1 transcript levels, potentially through inhibition of NMD, COL7A1 mRNA 
was measured using quantitative-PCR (QPCR). Overall base-line levels of COL7A1 were not 
consistently reduced in PTC harboring RDEB keratinocytes while the single RDEB fibroblast 
line tested had around 80% of wild-type levels (Figure 3a). Treatment with amlexanox, but not 
gentamicin, significantly increased mRNA abundance in both RDEB keratinocytes and 
fibroblasts with the exception of p.Q251X/p.Q251X keratinocytes.  In those cells (3 out of 4) that 
did show increase in transcript levels after amlexanox treatment, COL7A1 expression was around 
2-fold or higher compared to untreated control cells (Figure 3b). Cycloheximide was used as a 
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positive control for increase in transcript levels as previously described (Schneider-Poetsch et al., 
2010). 
UPF1 is an RNA helicase essential for NMD triggered by premature termination of translation 
upstream of the last exon-exon junction (Isken et al., 2008). It has been shown that stabilization 
of either the non-phosphorylated or the phosphorylated form of UPF1 inhibits NMD (Kurosaki et 
al., 2014). As amlexanox increased transcript levels of COL7A1 in 3 out of 4 RDEB cells, UPF1 
levels were evaluated by Western blotting. Read-through efficiency correlated with an increase 
in phosphorylated form of UPF1 (UPF1-P) in all RDEB cells tested. No increase in UPF1-P was 
observed in RDEB cells which did not result in read-through with amlexanox treatment (data not 
shown). Increase in UPF1-P was lowest for the single cell population which did read-through but 
did not exhibit increased transcript levels after amlexanox treatment (p.Q251X/p.Q251X 
keratinocytes). 
 
DISCUSSION 
Previous studies have reported that PTC read-through is both codon and context dependent 
(Manuvakhova et al., 2000; McCaughan et al., 1995). Not only the specific sequence of the stop 
codon but also the nucleotide immediately following the stop codon has been shown to affect the 
amount of read-through product. In addition, endogenous (natural) read-through is a mechanism 
that governs protein isoform expression, most notably demonstrated in Drosophila (Jungreis et 
al., 2011), and is both tissue specific and dependent on the 3’ nucleotide context (Prieto-Godino 
et al., 2016). These findings suggest that the termination of translation is dependent on factors in 
addition to the precise trinucleotide sequence of the PTC. The data presented here agree with 
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results pertaining to 3’ nucleotide context when compared with other read-through studies 
(Table 1). Among the stop signals tested so far the highest efficacy of read-through was 
observed in the UGA-C sequence and lowest, or no efficacy in the UGA-G stop codon 
combination (Table 1). However, there was inconsistency with p.R578X and p.R1933X 
mutations which did not read-through in two samples (RDEB107F and RDEB116K) yet did 
show read-through in three other samples (RDEB13K, RDEB5K, and RDEB115K) even though 
in each case the stop codon and the 3’ nucleotide were identical. In this respect it is of interest to 
note that those RDEB cells which showed read-through with amlexanox also showed read-
through with gentamicin and had endogenous full length type VII collagen in the untreated 
control, presumably as result of endogenous "leaky" PTC mutation (albeit at much lower levels). 
This observation suggests that read-through is primarily possible in those cells with an 
endogenous level of read-through and that this read-through is dependent on as yet unidentified 
factors. Such factors may well be potential disease modifiers in RDEB patients with PTC 
mutations. Additionally, these observations may imply that both gentamicin and amlexanox are 
acting to enhance read-through of PTC mutations in COL7A1 rather than initiating read-through.  
When comparing gentamicin with amlexanox, the data presented here demonstrate that 
amlexanox treatment results in greater levels of full length type VII collagen in 8/10 cells 
showing read-through while gentamicin treatment resulted in greater levels in 2/10 cells. We 
attribute this to different mechanisms of action, as amlexanox has been identified as an inhibitor 
of NMD (Gonzalez-Hilarion et al., 2012) while gentamicin, as an aminoglycoside, is thought to 
act on the ribosome (Yoshizawa et al., 1998). Indeed,  mRNA data at 24 hours after treatment 
(Figure 3b) identifies increase with amlexanox and not gentamicin, in keeping with previous 
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studies showing gentamicin induces transcript increase after 48 hours (Baradaran-Heravi  et al., 
2016), presumably due to feedback as a result of read-through. 
Although it has not been demonstrated which amino acid is inserted into the site of the PTC, the 
increase in type VII collagen harvested from amlexanox treated RDEB culture medium suggests 
that read-through type VII collagen is both stable and functional (Figure 2b). This conclusion is 
supported by correct linear deposition of read-through type VII collagen at the DEJ in 
organotypic culture (Figure 2c). This is not surprising considering that most mutations which 
affect the stability of the protein result in glycine substitutions in the collagen triple helix 
(Christiano et al., 1996; Cserhalmi-Friedman et al., 1997) and the mutations tested here did not 
affect glycine residues (Table 1).  
It has been suggested that around 30% of wild type levels of type VII collagen provide normal 
function in a murine model of RDEB (Nystrom et al., 2013) and that type VII collagen has a 
half-life of ~30 days (Kuhl et al., 2016). The study presented here shows that the amount of read-
through type VII collagen synthesized after a 48 hour treatment with amlexanox in vitro varies 
between 8% and 80% (Figure 1), as compared to healthy control cells. These results are 
promising since even a low level of read-through type VII collagen could potentially accumulate 
with continued treatment, and improve the adhesion of epidermis and dermis at the DEJ over 
time, resulting in improved quality of life for patients.  
It should be pointed out that the concentration of amlexanox used in this study is higher than that 
described in the serum of animals receiving 100 mg/kg oral amlexanox, which results in >5µM 
serum concentration (Reilly et al., 2013), and is a lower concentration than 50µM which is the 
lowest dose examined here, and shown to lead to read-through (Figure S2). Consequently, 
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further work will be required to ascertain the correct, tolerable dose, needed to elicit read-
through in RDEB patients.  
Other compounds which have shown ability to read-through PTC mutations are in clinical use, 
most notably PTC124 (ataluren) which was approved for treatment of Duchenne muscular 
dystrophy (Finkel, 2010). However, two independent studies have shown that PTC124 is not able 
to induce read-through of PTC mutations in COL7A1, thus suggesting PTC124 will not be 
suitable for RDEB (Cogan et al., 2014; McElroy et al., 2013).  
Recent clinical trials have raised hope for RDEB patient treatment but a cure remains elusive as a 
result of complications and limitations within each approach (Uitto et al., 2016). Amlexanox is 
an FDA approved drug for mouth ulcers and currently in phase II clinical trial for type II 
diabetes and for non-fatty liver disease (www.clinicaltrials.gov) where patients are treated orally 
(25 mg/kg) with no adverse side effects reported. Because amlexanox has been in clinical use 
both topically and orally, drug pharmacokinetics and toxicity profiles have already been 
established.  That, coupled with the pre-clinical data reported here, suggests the possibility of 
rapid translation into clinical practice in RDEB patients. Furthermore, amlexanox has been 
shown to possess anti-inflammatory properties (Saijo et al., 1985) which may have additional 
benefit for patients in the current context. Indeed, it is conceivable that a reduction in 
inflammatory processes may reduce proteolytic degradation within the environment of RDEB 
wounds leading to improved stability of type VII collagen.  
In conclusion, this study demonstrates the feasibility of amlexanox to synthesize full length type 
VII collagen by read-through of PTC mutations in COL7A1 in RDEB patient derived cells. The 
data show that amlexanox could potentially benefit RDEB patients by gradually increasing type 
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VII collagen levels at the DEJ while circumventing adverse side effects reported for other read-
through approaches.   
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MATERIALS & METHODS 
Cell cultures 
Cells were isolated from skin biopsies taken as part of routine surgical or diagnostic procedures. 
Informed written consent was obtained from each patient or in the case of under-aged children 
from their parents or guardian. This study was performed in accordance with the Helsinki 
declaration. All cells were cultured at 37o C at 5% CO2. Human fibroblasts were grown in 
Dulbecco's modified essential medium (DMEM, Corning cellgro, Mediatech Inc, Manassas, VA) 
supplemented with 10% fetal bovine serum (FBS, PEAK Serum, Cat PS-FB1, Colorado, USA).  
Keratinocytes and fibroblasts were immortalized using the E6 and E7 genes of human 
papillomavirus as described (Halbert et al., 1991). RDEB and normal keratinocytes were 
cultured in DMEM/Ham's F12 medium (3:1) supplemented with 10% FBS, 10 ng/ml of 
epidermal growth factor, 10-10 M cholera toxin, 0.4 µg/ml of hydrocortisone, 5 µg/ml of 
transferrin, 5 µg/ml of insulin and 5 µg/ml liothyronine. All media contained ascorbic acid (150 
µM). 
Drug treatment and western blot analysis 
Fibroblasts or keratinocytes were plated in a 100 mm dish at 8x105 to achieve 70-80% 
confluence the following day, when medium was changed with vehicle or either 250 µM 
amlexanox (Adipogen Life Sciences, San Diego, CA) or 1 mM gentamicin (G1264, Sigma 
Aldrich, St. Louis, MO). Medium was then changed daily containing freshly dissolved drug and 
after 48 hours of treatment cells were lysed with radioimmunoprecipitation assay buffer. Lysate 
was placed in a centrifuge for 5 minutes at 4oC, and the supernatant was mixed with a 6x 
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Laemmli loading buffer. Before loading onto SDS-PAGE, the samples were boiled for 5 minutes 
at 95oC. For type VII collagen detection, 90 µg of protein was loaded on a 6% acrylamide gel. 
Primary antibodies used were: polyclonal rabbit antibody raised against the NC1 domain of type 
VII collagen (kindly provided by Dr. Mei Chen, USC) (dilution 1:4,000); UPF1 (Cell Signaling, 
Beverly, MA) (dilution 1:1,000), UPF1-P (Ser1127, EMD Millipore, Billerica, MA) (dilution 
1:1,000); and β-actin – (Santa Cruz Biotechnology, Dallas, TX) (dilution 1:5,000). Resolved 
proteins were transferred onto nitrocellulose membrane with a BioRad Trans-Blot-Turbo (Bio-
Rad, Hercules, CA), blocked in PBS-0.1% Tween with 5% milk or 5% BSA according to 
requirements of the primary antibody, and incubated overnight with the primary antibody. After 
incubation with IgG-HRP conjugated secondary antibody (Santa Cruz Biotechnology), 
membrane was incubated with Pierce ECL Western blotting substrate (Fisher Scientific, 
Waltham, MA) and exposed to CL-XPosure X-ray film (Fisher Scientific, Waltham, MA).   
Protein Quantification 
Total cell lysates were quantified with Pierce bicinchoninic assay Protein Assay kit (Fisher 
Scientific, Waltham, MA) and 90 µg of protein were loaded onto SDS-PAGE gel. Western blot 
signal was quantified with Image J. Type VII collagen was quantified relative to β-actin and to 
non-treated control. UPF1-P was quantified relative to total UPF1 protein amount and non-
treated control.  
Metabolic activity assay 
Cells were seeded in 96-well plate (1x104 cells/ well) and incubated with given doses of the 
respective drug for 48 hours as described. After 48 hours the medium was changed with DMEM 
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10% FBS + WST-1 substrate (Roche Diagnostics, Manheim, Germany) (final WST-1 
concentration 10%). After 30 minutes incubation at 37oC the absorbance was measured using 
Flex Station 3 plate reader (Molecular Devices, Sunnyvale, CA) at 450 nm. 
Live/Dead Cell Assay 
Cells were seeded in a black 96 well plate (3x104 cells/ well) and treated over 48 hours with 
amlexanox. After 48 hours a working solution of 6 µM calcein AM and 6 µM EtD-III was added 
to the cells according to manufacturer’s instructions (EarlyTox Live/Dead Assay; Molecular 
Devices, Sunnyvale, CA). After 40 minutes of incubation at room temperature in the dark, 
fluorescence was measured with Flex Station 3 plate reader (Molecular Devices, Sunnyvale, CA) 
at two wavelengths – excitation at 495 nm and emission at 530 nm; excitation at 530 nm and 
emission at 645 nm. 
qRT-PCR 
Keratinocytes and fibroblasts were plated in six well plates for 90% confluence the next day. 
Cells were treated with the respective drug for 24 hours and total RNA was isolated using 
RNeasy Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. RNA 
extractions were quantified using a NanoDrop Spectrophotometer (Fisher Scientific, Waltham, 
MA) and 1.5 µg RNA was used for cDNA synthesis using SuperScript III First-Strand Synthesis 
System (Invitrogen, Life Technologies, Carlsbad, CA). For detection of COL7A1 expression, the 
following primers were used: forward primer GGCTGCAATTCTCCATGTGG, and reverse 
CTGTGAGGCAACTCGCTTCA. For ACTB amplification, the following primers were used: 
forward CATGTACGTTGCTATCCAGGC, and reverse CTCCTTAATGTCACGCACGAT. For 
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qPCR, SYBR Select Master mix (Life technologies, Carlsbad, CA) was used and cDNA samples 
were diluted 1:25 to serve as template. Experiments were performed in triplicate.  
Organotypic skin equivalents 
Bovine fibrinogen (90% clottable, MP Biomedicals, Santa Ana, CA) was dissolved in 1.1% 
NaCl at 37oC for 4 hours and then filtered with a 0.45 µm nylon membrane filter. Fibroblasts 
were collected with the use of trypsin and a centrifuge, and re-suspended in media to a final 
concentration 2x106 cells per ml. 150 µl of this cell suspension was mixed with 1 ml of thrombin 
(3 IU - Sigma Aldrich, St. Louis, MO),  and this cell/thrombin mix was added to fibrinogen at a 
ratio of 1:1. The mixture was quickly but gently distributed 1 ml/well into a 24-well plate and 
incubated at 37oC. After 20 minutes medium supplemented with ascorbic acid and aprotinin 
(Sigma, St. Louis, MO; final concentration 10 µg/ml) was added. The matrices were left to 
mature for 5-7 days while medium was changed every other day. Keratinocytes were plated on 
top at 2x106 per well and on the next day the culture was raised to the air-liquid interface on a 
metal grid and treatment with amlexanox was started; medium was changed every other day with 
fresh drug, ascorbic acid and aprotinin. Cultures were collected at one or two weeks of treatment 
and frozen with OCT in liquid nitrogen cooled isopentane. 8 µM sections were cut using a 
cryostat (AVANTIK QS11) and immunostained with the polyclonal type VII collagen antibody 
at a dilution of 1:800. Nuclei were counterstained with DAPI (Invitrogen, Carlsbad, CA). 
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Table 1: Cells used in this study. The table shows the name of cell lines, their mutations, 
immortalization conditions, the nucleotide sequence of the stop codon mutation and immediately 
following, and whether the cell line responded to read-through treatment. 
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Cell line 
name 
Mutation Condition Stop 
codon 
Nucleotide 
after PTC 
Read-
through 
RDEB53K p.R669X/p.R669X HpV 
immortalized, 
cSCC 
C->T 
TGA 
G NO 
RDEB14K p.Q251X/p.Q251X HpV 
immortalized 
C->T 
TAG 
T YES 
RDEB13K p.G2073D/p.R578X HpV 
immortalized 
C->T 
TGA 
G YES 
RDEB101K/F p.R669X/p.R669X Primary, 
HpV 
immortalized 
C->T 
TGA 
G NO 
RDEB102K/F p.R2814X/p.R2814X Primary,HpV 
immortalized 
C->T 
TGA 
C YES 
RDEB5K p.R578X/p.Q906X Primary C->T 
TGA/TAG 
G/G YES 
RDEB3K p.R525X/- cSCC C-> T 
TGA 
G NO 
RDEB107F p.R578X/p.R2492X HpV 
immortalized 
C->T 
TGA/TGA 
G/G NO 
RDEB111K p.R2610X/p.R2610X HpV 
immortalized 
C->T 
TGA 
G YES 
RDEB112K p.R1343X/p.R2069C HpV 
immortalized 
C->T 
TGA 
G YES 
RDEB110K p.R2338X/p.R2338X HpV 
immortalized 
C->T 
TGA/TGA 
G NO 
RDEB113K p.R1630X/p.R2069C HpV 
immortalized 
C->T 
TGA 
G YES 
RDEB115K c.4249delG/p.R1933X HpV 
immortalized 
C->T 
TGA 
G YES 
RDEB116K p.R1933X/p.R1933X HpV 
immortalized 
C->T 
TGA 
G NO 
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FIGURE LEGENDS 
 
Figure 1: Amlexanox induces full length type VII collagen synthesis in RDEB patient derived 
cells. Keratinocytes (a and b) and fibroblasts (c) isolated from different RDEB patients were 
treated with 250 µM amlexanox (A) or gentamicin 1 mM (G). Expression of type VII collagen 
after treatment was compared to normal human keratinocytes or fibroblasts (NHK or NHF) using 
Western blotting. For optimization of detection, the amount of protein loaded from RDEB 
keratinocytes (not fibroblasts) was twice the amount of protein loaded from control cells. Levels 
of type VII collagen expression were quantified in image J relative to β-actin and non-treated 
controls (NT). Graph shows protein levels as a percentage of normal cells. 
 
Figure 2:  Read-through type VII collagen is stable and locates to the dermal-epidermal junction. 
RDEB cells harboring G2073D / R578X mutations and R2610X/R2610X mutations were 
assessed for levels of intracellular type VII collagen (a) and levels of secreted type VII collagen 
(b) using Western blotting. Treatment with amlexanox and gentamicin stabilizes secreted levels 
of the protein. For optimization of detection, the amount of protein loaded from RDEB cells was 
twice the amount of protein loaded from control cells. (c) Treatment of organotypic skin cultures 
with amlexanox for two weeks increases type VII collagen deposition at the dermal-epidermal 
junction (DEJ). Organotypic skin cultures were prepared using RDEB cells or wild type cells, 
and synthesis of type VII collagen at the DEJ was evaluated using immunofluorescence staining. 
The magnification bar = 400 µM. 
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Figure 3: Amlexanox increases transcript levels of COL7A1 in 3 out of 4 RDEB patient cells. (a) 
Evaluation of baseline levels of COL7A1 transcript compared to normal keratinocytes and 
fibroblasts shows relatively similar levels of expression. (b) Treatment with amlexanox (250 
µM) increases COL7A1 transcript in all but one population of RDEB cells. Gentamicin (1 mM).  
 
Figure 4: Read-through synthesis of type VII collagen correlates with increase in UPF1 
phosphorylation state. RDEB or wild type cells were cultured in 100 mm dishes and treated with 
either amlexanox or gentamicin for 48 hours. Levels of UPF1-P were quantified in image J 
relative to total levels of UPF1 and non-treated controls.  
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